Compare Novo Nordisk A/S (NVO) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs United Parcel Service Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while United Parcel Service Inc trades at $116.02 (market cap $96.18B). The key difference: Novo Nordisk A/S is far larger — about 2.3× United Parcel Service Inc's market cap, and United Parcel Service Inc pays the higher dividend (5.8%). Which is the better fit depends on your goals.
| NVO | UPS | |
|---|---|---|
Market Cap | $220.53B | $96.18B |
Sector | Health | Industrials |
52-Week High | $71.70 | $120.00 |
52-Week Low | $35.29 | $82.58 |
Enterprise Value | $239.49B | $119.04B |
Dividend Yield | 3.63% | 5.8% |
Volume | — | 2,288,643 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
UPS stock trades at $116.34, down 1.17% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 results due July 28, 2026. Revenue declined to $88.66 billion in 2025, but cost controls supported a net margin of 5.94% and strong ROE of 33.41%. The company maintains solid cash flow from operations of $8.45 billion and recently paid a $1.64 dividend.
Outlook is mixed: cost-cutting and potential Q2 earnings beat offer upside, but revenue pressure and Amazon's logistics expansion pose risks. Analysts are cautiously optimistic with a $112 consensus target, slightly below current price. Key investor focus is on Q2 results and updated guidance for second-half 2026 inflection point prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
